Combinations of elevated tissue miRNA‑17‑92 cluster expression and serum prostate‑specific antigen as potential diagnostic biomarkers for prostate cancer

Abstract

Abstract. The aim of the present study was to investigate the effectiveness of the miR-17-92 cluster as a disease progression marker in prostate cancer (PCa). Reverse transcription-quantitative polymerase chain reaction analysis was used to detect the microRNA (miR)-17-92 cluster expression levels in tissues from patients with PCa or benign prostatic hyperplasia (BPH), in addition to in PCa and BPH cell lines. Spearman correlation was used for comparison and estimation of correlations between miRNA expression levels and clinicopathological characteristics such as the Gleason score and prostate-specific antigen (PSA). Receiver operating curve (ROC) analysis was performed for evaluation of specificity and sensitivity of miR-17-92 cluster expression levels for discriminating patients with PCa from patients with BPH. Kaplan-Meier analysis was plotted to investigate the predictive potential of miR-17-92 cluster for PCa biochemical recurrence. Expression of the majority of miRNAs in the miR-17-92 cluster was identified to be significantly increased in PCa tissues and cell lines. Bivariate correlation analysis indicated that the high expression of unregulated miRNAs was positively correlated with Gleason grade, but had no significant association with PSA. ROC curves demonstrated that high expression of miR-17-92 cluster predicted a higher diagnostic accuracy compared with PSA. Improved discriminating quotients were observed when combinations of unregulated miRNAs with PSA were used. Survival analysis confirmed a high combined miRNA score of miR-17-92 cluster was associated with shorter biochemical recurrence interval. miR-17-92 cluster could be a potential diagnostic and prognostic biomarker for PCa, and the combination of the miR-17-92 cluster and serum PSA may enhance the accuracy for diagnosis of PCa.

The SOX4/miR-17-92/RB1 Axis Promotes Prostate Cancer Progression

“…Previous reports have shown that many miRNAs are involved in promoting PCa progression including miR-17-92 [34], [35], miR-106b-25 [36], [37] and miR-424 [38]. However, it remains unclear whether or not SOX4 regulates the miRNAs expression in PCa cells.…”

Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer

“…Yang and colleagues showed that miR-17-5p and miR-17-3p promote prostate cancer proliferation and invasion by targeting the same protein, namely, tissue inhibitor of metalloproteinase 3 (22). Feng and colleagues reported that the expression levels of miR-17-3p are significantly higher in prostate cancer tissues than in BPH (23). These reports suggest that elevated levels of miR-17-3p in serum are associated with prostate cancer and reflect disease progression.…”

Association of High miR-182 Levels with Low-Risk Prostate Cancer

“…Dysregulated miRs in PCa have been proposed to contribute to disease progression, as well as act as potential biomarkers for the presence of PCa or to predict PCa outcomes. 11 , 13 , 45 , 46 , 47 We examined the association of miR-182 expression with clinical markers of PCa aggressiveness in a TMA cohort and proposed gene and pathway targets of miR-182 in prostate epithelium using LCM-collected tissue. This study yielded expected and unexpected expression patterns for miR-182 in PCa, which prompted us to examine its mRNA targets, ultimately determining that PCa with high levels of miR-182 behave less aggressively than tumors with less overexpression of this oncomiR.…”

“…Dysregulated miRs in PCa have been proposed to contribute to disease progression, as well as act as potential biomarkers for the presence of PCa or to predict PCa outcomes 11, 13, 45, 46, 47. We examined the association of miR-182 expression with clinical markers of PCa aggressiveness in a TMA cohort and proposed gene and pathway targets of miR-182 in prostate epithelium using LCM-collected tissue.…”